Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 35, Issue 5, Pages 481–488
Research Article

Role of Immunomarkers in the Clinicopathological Analysis of Unicystic Ameloblastoma

1Department of Oral and Maxillofacial Pathology, Manipal College of Dental Sciences, Manipal University, Manipal, Karnataka 576104, India
2Department of Community Medicine, Kasturba Medical College, Manipal University, Manipal, Karnataka 576104, India

Received 7 June 2013; Accepted 29 August 2013

Academic Editor: Gunter Haroske

Copyright © 2013 Parul Sah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Purpose. The clinical behavior of unicystic ameloblastoma varies according to its subtype. The assessment of its proliferative capacity, neovascularization, and invasiveness using relevant immunomarkers may aid in appropriate surgical therapeutic protocol. Methods. 18 cases of clinically and histologically confirmed unicystic ameloblastoma, categorized as luminal, intraluminal, or mural subtypes, were analyzed retrospectively. Immunomarkers such as Ki-67, CD34, MMP-2, and MMP-9 were studied to evaluate their behavior. Results. Labeling index of Ki-67 was 4.25% in the intraluminal subtype, compared with 2.14% in the luminal and 4.04% in the mural variant ( ). CD34 immunostaining was significantly higher in the mural variant (43 per high power field) than the other two subtypes ( ). MMP-2 and MMP-9 were strongly expressed in mural, moderately in intraluminal, and weakly to absent in luminal variant. Conclusions. High proliferative index, angiogenesis, and protease activity in the mural ameloblastoma, ascertained by the expression of these markers, confirm its aggressive phenotype. The intraluminal and luminal subtype exhibiting decreased expression are compatible with their indolent clinical behavior.